Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, phase II UK multi-centre study to determine reactogenicity and immunogenicity of booster vaccination against ancestral and novel variants of SARS-CoV-2

X
Trial Profile

A randomised, phase II UK multi-centre study to determine reactogenicity and immunogenicity of booster vaccination against ancestral and novel variants of SARS-CoV-2

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; NVX CoV 2373 (Primary) ; Tozinameran (Primary) ; VLA 2001 (Primary) ; Zorecimeran (Primary) ; Aluminium hydroxide; CpG; Matrix M; Meningococcal vaccine groups A C Y W-135 conjugate
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Acronyms Cov-Boost
  • Most Recent Events

    • 19 Apr 2023 Results of 8-month analysis (n=817) comparing the immunogenicity and kinetics of responses to third doses of vaccines from day 28 to day 242 following third doses in seven study arms, published in the Journal of Infection.
    • 18 Jan 2023 According to Novavax media release, the company announced that the partner SK biosciences has received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety (KMFDS) for NVX-CoV2373 for use as a booster for active immunization to prevent COVID-19 in adults aged 18 and older. The approval was based on the data from this study.
    • 29 Nov 2022 According to a Novavax media release, based on supportive data from this trial, the WHO has issued an updated Emergency Use Listing (EUL) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top